高危型人乳头瘤病毒持续感染的转阴治疗方法探讨

doi:10.3877/cma.j.issn.1673-5250.2013.06.018

中华妇幼临床医学杂志(电子版) ›› 2013, Vol. 09 ›› Issue (06) : 798 -800. doi: 10.3877/cma.j.issn.1673-5250.2013.06.018

所属专题：文献；

论著

高危型人乳头瘤病毒持续感染的转阴治疗方法探讨

陈曾燕¹, 何陈云¹^,^*^,^*(

), 费国华¹, 钱云¹, 陆泓¹

^1. 226361　江苏南通，南通市肿瘤医院妇科

收稿日期:2013-08-09 修回日期:2013-10-14 出版日期:2013-12-01
通信作者: 何陈云

Investigation of Treatment for Overcast Rate of High-Risk HPV Persistent Infection

Zeng-yan CHEN¹, Chen-yun HE¹(), Guo-hua FEI¹, Yun QIAN¹, Hong LU¹

^1. Department of Gynaecology, Tumor Hospital of Nantong University, Nantong 226361, Jiangsu Province, China

Received:2013-08-09 Revised:2013-10-14 Published:2013-12-01
Corresponding author: Chen-yun HE
About author:
(Corresponding author : HE Chen-yun,Email: bjhcy2010@126.com)

全文 ( ) 下载PDF ( ) 导出引用

目的

探讨"热疗联合长效抗菌材料"治疗生殖道高危型人乳头瘤病毒(HPV)感染的有效性及可行性。

方法

选择2009年1月至2010年12月南通市肿瘤医院收治的182例宫颈癌治愈后生殖道高危型HPV检查仍呈阳性并接受转阴治疗的患者为研究对象。将其按照治疗方法的不同分为3组：热疗+ 长效抗菌材料组(n =60)，长效抗菌材料治疗组(n = 56)及热疗组(n=66)。3组病例治疗频率均为2次/d，治疗7 d为一个疗程。1个月后检测生殖道高危性HPV有无转阴。选择未接受转阴治疗并愿意随访观察的患者（宫颈癌治愈后生殖道高危型HPV仍呈阳性）为对照组(n = 72)，定期随访一年，观察自然转阴率（本研究遵循的程序符合南通市肿瘤医院人体试验委员会制定的伦理学标准，得到该委员会批准，征得受试对象知情同意，并与之签署临床研究知情同意书）。各组患者年龄、KPS功能状态评分（可评定对抗肿瘤治疗的耐受力）等一般情况比较，差异无统计学意义(P>0. 05)。

结果

高危性HPV转阴率分别为：热疗+ 长效抗菌材料组(85.0%)，长效抗菌材料治疗组(46.4%)，热疗组(24.2%)，对照组(8.3%)。接受转阴治疗的3组间HPV转阴率比较，差异有统计学意义(P<0. 005)，热疗+长效抗菌材料组转阴率明显高于另两组。治疗组与对照组HPV转阴率比较，差异有统计学意义(P<0.005)。

结论

"热疗联合长效抗菌材料"能更有效的治疗生殖道高危型HPV感染。

关键词: 热疗, 抗菌剂, 人乳头瘤病毒

Objective

To explore the efficacy and feasibility of "hyperthermia combined with long-lasting antibacterial materials" in treatment of high-risk HPV infection in genital tract.

Methods

182 cases with high-risk HPV infection in genital tract after cervical cancer cure from January 2009 to December 2010 in our hospital were randomly divided into three groups: group of hyperthermia combined with long-lasting antibacterial materials (n = 60); group of long-lasting antibacterial materials (n = 56) and group of hyperthermia(n = 66). All cases were treated twice a day per week and the darkening was detected after one month. The control group (n=72) who were not treated as above and will to follow up for one year and the natural negative rate was observed. The study protocol was approved by the Ethical Review Board of Investigation in Human Beings of Tumor Hospital of Nantong University. Informed consent was obtained from each participating patient. The general data such as patients' age, KPS function score had no significant difference(P>0. 05).

Results

The darkening of combined treatment group was 85. 0% , much higher than 46. 4% of antibacterial materials group and 24. 2% of hyperthermia group, while the darkening of the control group was only 8. 3 The difference was significant (P< 0. 005). Comparison of overcast rate between therapy group and control group had significant difference ( P<0. 005).

Conclusions

"Hyperthermia combined with long-lasting antibacterial materials" in treatment of high-risk HPV infection in genital tract is more effective.

Key words: hyperthermia, induced, anti-bacterial agents, human papilloma virus

表1 3种方法治疗后HR-HPV转阴率比较[n(%)]

Table 1 Comparison of HR-HPV overcast rate among three treatment groups[n(%)]

组别	n	HP-HPV转阴率
热疗+长效抗菌材料组	60	51(85.0)^a
长效抗菌剂治疗组	56	26(46.4)^b
热疗组	66	16(24.2)^c

表1 3种方法治疗后HR-HPV转阴率比较[n(%)]

Table 1 Comparison of HR-HPV overcast rate among three treatment groups[n(%)]

组别	n	HP-HPV转阴率
热疗+长效抗菌材料组	60	51(85.0)^a
长效抗菌剂治疗组	56	26(46.4)^b
热疗组	66	16(24.2)^c

表2 治疗组与对照组HR-HPV转阴率比较[n(%)]

Table 2 Comparison of HR-HPV overcast rate between the treatment group and the control group[n(%)]

组别	n	HP-HPV转阴率
治疗组	182	93(51. 1)
对照组	72	6 (8.3)
χ²	?	39. 67
P	?	0. 00

表2 治疗组与对照组HR-HPV转阴率比较[n(%)]

Table 2 Comparison of HR-HPV overcast rate between the treatment group and the control group[n(%)]

组别	n	HP-HPV转阴率
治疗组	182	93(51. 1)
对照组	72	6 (8.3)
χ²	?	39. 67
P	?	0. 00

1	Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer[J]. J Natl Cancer Inst,2011,103(5) :368-383.
2	Li N, Franceschi S, Howell-Jons R, et al. Human papillowavirus type distribution in 30 848 invasive cervical cancers worldwide: Variation by geographical region, histolgical type and year of publication[J]. Int J Cancer,2011,128(4) :927-935.
3	Liu JH, Lang JH. Human papillomavirus and cervical cancer and precancerous lesions [A]. In: Lian LJ,ed. Pediatrics Linqiaozhi Gynecologic Oncology. 4th ed. Beijing: People's Medical Publishing House, 2006,279.
4	Yang J, Luo J. Study on correlation between progression of cervical lesions and viral load of high-risk human papillomavirus [J]. Pract Prev Med,2010,4(17): 646-647.
5	Moberg M, Gustavsson I, Wilander E, et al. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma[J]. Br J Cancer, 2008,92(5):891-894.
6	Ju XZ, Yang JM, Zhou XY, et al. EMMPRIN expression as a prognostic factor in radio therapy of cervical cancer[J]. Clin Cancer Res,2008,14:494-495.
7	Kang YX, Zhang HL. Research development of mechanism by hyperthermia in tumor[J]. Mod Oncol, 2008,3(16) :473.
8	Yang YZ. The progress of diagnosis and treatment in HPV testing associated with cervical lesions [J]. J Chin Mod Gynaecol Obstet, 2007,4(4):304-307.

[1]	刘卓, 陶金华, 沈金闻, 李德川, 朱玉萍, 罗加林. 局部晚期直肠癌术前同步放射治疗及化学治疗联合热疗67例疗效分析[J]. 中华危重症医学杂志(电子版), 2021, 14(03): 217-221.
[2]	卫怡妙, 李亚芹, 赵卫红. 环状RNA与宫颈癌发病机制的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(05): 512-516.
[3]	杨春, 陈悦悦, 周琳, 张丹. 阴道微环境失衡与高危型人乳头瘤病毒持续感染[J]. 中华妇幼临床医学杂志(电子版), 2021, 17(06): 740-744.
[4]	薛钰, 吴丹, 李柱南, 张峥嵘, 林婧, 许颖, 熊振虹, 曹丹. CO₂激光治疗宫颈上皮内瘤变和阴道上皮内瘤变临床疗效[J]. 中华妇幼临床医学杂志(电子版), 2020, 16(04): 483-491.
[5]	陈锐, 冯凌, 付艳, 王黎明, 谭洁, 廖秦平. 派特灵治疗宫颈病变术后高危型人乳头瘤病毒持续呈阳性的临床研究[J]. 中华妇幼临床医学杂志(电子版), 2020, 16(04): 438-443.
[6]	王文豪, 王卉, 郝敏. 宫颈癌与叶酸相关信号通路的研究进展[J]. 中华妇幼临床医学杂志(电子版), 2020, 16(02): 245-248.
[7]	李懿雪, 潘婷, 林焕彩, 周燕. 植物源性天然产物在口腔细菌感染性疾病中的研究进展[J]. 中华口腔医学研究杂志(电子版), 2023, 17(03): 188-196.
[8]	李沐宸, 温星桥. 前列腺癌与微生物的联系[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(02): 188-192.
[9]	王姮, 张瑞恒, 刘月明, 魏文斌. 巩膜外敷贴放射后补充经瞳孔温热疗法治疗脉络膜黑色素瘤的临床研究[J]. 中华眼科医学杂志(电子版), 2023, 13(01): 18-23.
[10]	李秘, 邱华娟, 纪燕琴, 周明辉. P16、Ki67表达及病毒载量对宫颈上皮内瘤变Ⅱ合并高危型人乳头瘤病毒感染患者病变转归的影响[J]. 中华临床医师杂志(电子版), 2023, 17(03): 272-278.
[11]	朱琳琳, 赵帆, 闫琳琳, 郑凤芝, 王静, 胡守奎. 北京京西地区女性高危型HPV感染状况及基因型分析[J]. 中华临床医师杂志(电子版), 2022, 16(09): 897-901.
[12]	杨旭梅, 金蓉蓉, 周慧玲, 蒋小芹, 于鸿. HPV疫苗研究进展及推广接种过程中的影响因素[J]. 中华临床医师杂志(电子版), 2021, 15(03): 218-223.
[13]	孔蕊, 姚群, 吴晓博, 张小红, 范颖. 高危型人乳头状瘤病毒感染类型及载量与子宫颈癌前病变严重程度及病变范围的相关性[J]. 中华临床医师杂志(电子版), 2020, 14(05): 376-379.
[14]	秦毓, 杨苗, 畅锴, 王舒宁. 山西省女性人乳头瘤病毒感染现状分析[J]. 中华临床实验室管理电子杂志, 2023, 11(02): 105-108.
[15]	尹嫚, 杨林青, 王云飞. 女性生殖道同期发生的黏液上皮化生和肿瘤的诊断学特征并文献复习[J]. 中华诊断学电子杂志, 2022, 10(03): 193-196.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Investigation of Treatment for Overcast Rate of High-Risk HPV Persistent Infection

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Investigation of Treatment for Overcast Rate of High-Risk HPV Persistent Infection